Figure 9.

Self-delivery of micellar nanoparticles prevent the PMN formation

(A) Schematic illustration of PLT/DOX/αGC nanoparticles and the mechanism of LT NPs interference of g-MDSCs recruitment.

(B) The percent of g-MDSCs (CD11b⁺ ly6g⁺ cells) in the lungs of healthy mice and B16F10 melanoma-bearing mice after different treatments (PBS, LMWH, LT, PLT). (means ± SD, n = 3, ∗∗∗P < 0.001)

(C) The percentage of cytotoxic T lymphocytes (CD8⁺ T cells) and CD4⁺ T helper cells in the lungs of healthy mice and B16F10 melanoma-bearing mice after different treatments. (means ± SD, n = 3, ∗P < 0.05, ∗∗P < 0.01)

(D) Schematic diagram of the establishment of tumors and treatment process.

(E) Photographs of the harvested lungs (left) and numbers of pulmonary nodules (right) from B16F10 melanoma-bearing mice receiving different treatments. PLT, phenylboronic acid (PBA)-low-molecular-weight heparin (LMWH)-tocopherol succinate (TOS); DOX, doxorubicin; α-GC, α-galactosylceramide; LT NPs, LMWH-TOS nanoparticles. (means ± SD, n = 4, ∗∗∗P < 0.001)

Reproduced with permission from Long et al.¹⁷⁴ Copyright 2020, American Chemical Society.